8-K: Calidi Biotherapeutics Announces Promising Preclinical Results for Systemic RTNova Platform

Calidi Biotherapeutics reports successful delivery of transient gene therapy payloads to tumors using its systemic RTNova platform, along with efficacy in killing over 60 tumor cell lines.

Summary

• Calidi Biotherapeutics announced positive preclinical results for its RTNova platform.
• The platform successfully delivered gene therapy payloads to targeted tumors.
• Calidi's tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.
• The RTNova platform is designed to treat advanced-stage metastatic cancers, including lung cancer.
• The platform uses an innovative vaccinia virus strain enveloped with a human cell membrane (EEV) to protect it in the bloodstream and target distant tumors.
• Once inside the tumor, the virotherapies selectively replicate and destroy tumor cells, inducing an immune response.
• New data showed that a single dose of a tumor-selective triple knockout (3KO) RT virus with a specific immunotherapeutic payload dramatically altered the tumor microenvironment.
• Leukocyte infiltration reached 80% for 3KO RT and 92% for the 3KO RT with the payload, compared to 46% for the untreated arm.
• These shifts in immune composition led to complete eradication of certain tumors in the preclinical model.
• Calidi believes its systemic platform can act as a viral vector to express therapeutic genes in target tumors.

Sentiment

Score: 8

Explanation: The document presents positive preclinical results, suggesting potential for future clinical success and partnerships. However, it's important to consider the inherent risks associated with biotechnology development and the forward-looking nature of the statements.

Positives

• The RTNova platform successfully delivered gene therapy payloads to targeted tumors.
• Calidi's tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell lines.
• The platform can act as a viral vector to express therapeutic genes in target tumors.
• The 3KO RT with payload resulted in complete eradication of certain tumors in the preclinical model.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Calidi may not be able to raise sufficient capital to support its clinical trials.
• Early results of clinical trials may not predict final results.
• Calidi may not receive FDA approval for its therapeutic candidates.

Future Outlook

The company anticipates upcoming key milestones, including reporting interim clinical results and dosing patients, and plans for future clinical trials.

Management Comments

• Allan Camaisa, Chief Executive Officer and Chairman at Calidi Biotherapeutics, stated that the company is excited to have shown that its systemic platform can act as a viral vector to express therapeutic genes in target tumors, maximizing the potential of the designed treatment.
• He also mentioned that this breakthrough allows the company to develop multiple assets for various indications, opening the door for potential partnerships opportunities.

Industry Context

This announcement positions Calidi Biotherapeutics in the competitive immuno-oncology space, focusing on novel approaches to deliver gene therapy and oncolytic viruses to treat advanced cancers. The systemic delivery platform addresses a key challenge in treating metastatic cancers where intratumoral administration is not feasible. Competitors in this space include companies developing viral vectors and oncolytic virus therapies, such as Amgen (Imlygic), Oncolytics Biotech, and Replimune.

Comparison to Industry Standards

• Amgen's Imlygic is an oncolytic virus therapy approved for melanoma, but it requires intratumoral injection, unlike Calidi's systemic approach.
• Companies like Oncolytics Biotech are developing systemic oncolytic virus therapies, but Calidi's approach of using stem cells to deliver the virus is a unique differentiator.
• Replimune is another player in the oncolytic virus space, focusing on engineering viruses to enhance immune stimulation, which aligns with Calidi's goal of inducing an immune response against cancer cells.
• The 92% leukocyte infiltration achieved by Calidi's 3KO RT with payload is a promising result compared to industry benchmarks for immune activation in preclinical models.

Stakeholder Impact

• Shareholders may react positively to the promising preclinical results.
• Employees may be motivated by the potential of the company's technology.
• Patients with advanced cancers may benefit from the development of new therapies based on the RTNova platform.
• Potential partners may be interested in collaborating with Calidi to develop and commercialize its technology.

Next Steps

• Calidi will continue to develop its RTNova platform and advance its therapeutic candidates through clinical trials.
• The company will explore potential partnership opportunities to expand the development and commercialization of its platform.

Key Dates